Content
@
https://opensea.io/collection/science-14
0 reply
0 recast
0 reaction
arob.base.eth π©
@arob1000
Very excited to announce that weβve dosed our first patient with our latest next-gen cancer immunotherapy drug which is broadly applicable to most solid tumors! We started working on this one in 2022. Itβs really cool to see how quickly a drug can go from an idea into the clinic. https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx
11 replies
9 recasts
34 reactions
BOβοΈB π©
@drmat
100 π Grats, Mr. Richard Lepke π
1 reply
0 recast
1 reaction
arob.base.eth π©
@arob1000
Exciting stuff! No clue who Richard Lepke is.
1 reply
0 recast
1 reaction
BOβοΈB π©
@drmat
Saw 'Richard Lepke' at the end of the link you sent β had me thinking that was your name, bro π
1 reply
0 recast
1 reaction
arob.base.eth π©
@arob1000
Ah nope, that's not me. Guess that is our PR guy!
0 reply
0 recast
1 reaction